Overview

A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

Status:
Completed

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effects on QTc interval in healthy males when administered a single dose of NKTR-118 compared with placebo and moxifloxacin. (QTc is a specific time interval that can be measured in a heart beat by taking Electrocardiogram (ECG))

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Fluoroquinolones
Moxifloxacin
Naloxegol
Norgestimate, ethinyl estradiol drug combination